Claims for Patent: 6,613,884

Summary for Patent: 6,613,884

Title:	Method for the removal/purification of serum albumins and means for use in the method
Abstract:	A method for removing a serum albumin from a mixture of other compounds by contacting said mixture with a ligand a) having affinity for and enabling selective binding of the serum albumin and b) being attached to a base matrix insoluble in the aqueous media used or being possible to attach to such a matrix after having become bound to the serum albumin, characterized in that said ligand is derived from an albumin binding bacterial cell surface receptor and that the ligand lacks the IgG-binding and/or .alpha..sub.2 -macroglobulin-binding ability found in native forms of these type of bacterial receptors. An albumin-binding ligand derived from a cell surface bacterial receptor and attached covalently to a carrier matrix, characterized in that the ligand is monovalent with respect to ability to bind a serum albumin. A method for removal of serum albumin from a sample that is to be assayed for non-serum albumin components. The characteristic feature is to subject the sample to affinity adsorption by an albumin-binding ligand derived from an albumin-binding receptor.
Inventor(s):	Johansson; Hans (Summit, NJ)
Assignee:	Amersham Biosciences AB (Uppsala, SE)
Application Number:	09/719,511
Patent Claims:	1. A method for separating human serum albumin from a mixture including a human serum albumin analogue, said method comprising: a) contacting a mixture containing human serum albumin and a human serum albumin analogue with a ligand wherein said ligand: i) is derived from a fragment of streptococcal protein G comprising the complete A3 albumin binding domain, said fragment further lacks IgG-binding ability or .alpha..sub.2 -macroglobulin-binding ability, or both; and ii) is directly or indirectly attached to a base matrix insoluble in aqueous media; or iii) is attached to a base matrix insoluble in aqueous media after formation of a human serum albumin-ligand complex; b) binding said human serum albumin to said ligand to form a complex; and c) separating said human serum albumin from the mixture comprising said human serum albumin analogue. 2. The method of claim 1, wherein said ligand contains one or more individual subunits that bind to serum albumin. 3. The method of claim 2, wherein said ligand contains only one serum albumin binding subunit. 4. The method of claim 1, wherein said mixture derives from a host that expresses human serum albumin as a heterologous protein. 5. The method of claim 1, wherein said ligand is covalently attached to said matrix. 6. The method of claim 5, wherein said ligand is covalently attached via one or more groups selected from the group consisting of: an amino group, a carboxy group and a mercapto group, present in an amino acid of the ligand. 7. The method of claim 1, further comprising eluting said human serum albumin from said base matrix and optionally, further processing it. 8. A method for separating human serum albumin, IgG and .alpha..sub.2 -macroglobulin from a mixture comprising a human serum albumin analogue, said method comprising: a) contacting a mixture comprising human serum albumin and a human serum albumin analogue with a ligand, wherein said ligand: i) is derived from a fragment of streptococcal protein G and comprises the complete A3 albumin binding domain; and ii) is directly or indirectly attached to a base matrix insoluble in aqueous media; or iii) is attached to a base matrix insoluble in aqueous media after formation of a human serum albumin-IgG-.alpha..sub.2 -macroglobulin-ligand complex; b) binding said human serum albumin, IgG and .alpha..sub.2 -macroglobulin with said ligand to form a complex; and c) separating said human serum albumin, IgG and .alpha..sub.2 -macroglobulin from the mixture comprising said human serum albumin analogue.

Details for Patent 6,613,884

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2018-06-18
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2018-06-18
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2018-06-18
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2018-06-18
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2018-06-18
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2018-06-18
Csl Behring Llc	ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5	albumin (human)	Injection	103955	03/17/2000		2018-06-18